NEW YORK--(BUSINESS WIRE)-- IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“IntelliCell”) or the (“Company”), December 27, 2010 IntelliCell filed its patent application with the US Patent office that will claim priority to its provisional US patent serial #61/427, 221 that was filed on December 27, 2010. The title of the patent application is Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use Thereof. It covers the methods of manufacturing using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within the adipose tissue, thereby obtaining multi-potent, mesenchymal or stromal vascular fractions for use in human subjects. These methods do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased number of cells which constitute the multi-potent, mesenchymal or stromal vascular fractions (about ten folds greater than methods which use collagenase to isolate these cells).
Dr. Steven Victor, the inventor, and CEO of IntelliCell BioSciences commented “we are extremely excited to have filed this patent in the US and around the world. The use of ultrasonic cavitation allows physicians to use less than 60cc’s of adipose tissue (fat) to manufacture approximately a half billion to 1.4 billion stromal vascular fraction cells (SVF cells) within five to ten minutes. The use of sound and water allows this manufacturing method to be utilized by physicians in the US underneath FDA (PHS Act Section 361 1271.10 (a)) of the health bill passed by Congress in 2009. This manufacturing method has significant cost and time advantages over any other method of producing SVF cells. These cells have been used around the world for conditions caused by inflammation, such as lower back pain, migraines, MS, autism, fibromyalgia, tinnitus, arthritis; tissue repair, such as growing cartilage for bone on bone knee repair; bone and gingival tissue (gum disease): cosmetic indications such as fat grafting, wrinkle removal and other cosmetic procedures. The success rate for these patients has been approximately 80% plus. We believe that the use of non-enzymatic SVF cell therapy will find its first applications in treating sports related injuries. We are proud to have numerous luminaries on our advisory board who are leaders in the sports medicine world. We anticipate significant revenues from the utilization of SVF cells from the various IntelliCell BioSciences Centers of Excellence in the year 2012.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioSciences is exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.
Investor Relations for IntelliCell BioSciences Inc.
Laurel Moody, 646-810-0608
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Pharmaceutical Other Health Research Other Science Science General Health